Drugs / T3
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT04725110 | Jan 2026 → Oct 2030 | COVID-19, acute respiratory distress syndrome | University of Minnesota | Withdrawn | No outcome recorded |
| Phase 2 | NCT02654041 | Mar 2016 → Jun 2017 | glioblastoma | Musli Thyropeutics Ltd. | Terminated | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00073242 | Jul 2000 → Jul 2015 | obesity disorder | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Unknown | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT05247476 | Oct 2021 → Mar 2022 | postsurgical hypothyroidism, thyroid gland papillary carcinoma | Zhongshan Hospital Xiamen University | Unknown | No outcome recorded |
| Phase 4 | NCT00021528 | Jul 2001 → Sep 2006 | major depressive disorder | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00903877 | May 2009 → Jun 2011 | fibromyalgia | Stanford University | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | T3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00073242 ↗ |
| Known as | Triiodothyronine | “T3 (Triiodothyronine)” NCT00021528 ↗ |
| Action | Restore | “Repletion of T3 following weight loss induced by dietary modification” NCT00073242 ↗ |
| Route | Oral | “Oral administration of T3 and Methimazole” NCT02654041 ↗ |